武汉云克隆科技股份有限公司

Abstract: Endothelial progenitor cells (EPCs) mobilization and homing are critical to the development of an anti-thrombosis and anti-stenosis tissue-engineered blood vessel. The growth and activation of blood vessels are supported by nerves. We investigated whether nerve growth factors (NGF) can promote EPCs mobilization and endothelialization of tissue-engineered blood vessels. In vitro, NGF promoted EPCs to form more colonies, stimulated human EPCs to differentiate into endothelial cells, and significantly enhanced EPCs migration. Flow cytometric analysis revealed that NGF treatment increased the number of EPCs in the peripheral circulation of C57BL/6 mice. Furthermore, the treatment of human EPCs with NGF facilitated their homing into wire-injured carotid arteries after injection into mice. Decellularized rat blood vessel matrix was incubated with EDC cross-linked collagen and bound to NGF protein using the bifunctional coupling agent N-succinmidyl3-(2-pyridyldit-hio) propionate (SPDP). The NGF-bound tissue-engineered blood vessel was implanted into rat carotid artery for 1 week and 1 month. NGF-bound blood vessels possessed significantly higher levels of endothelialization and patency than controls did. These results demonstrated that NGF can markedly increase EPCs mobilization and homing to vascular grafts. Neurotrophic factors such as NGF have a therapeutic potential for the construction of tissue-engineered blood vessels in vivo.

摘要：内皮祖细胞（EPCs）动员和归巢对抗血栓形成和抗狭窄组织工程血管的发展至关重要。神经支持血管的生长和活化。我们检测神经生长因子（NGF）是否能促进EPCs动员和组织工程血管的内皮化。在体外，NGF促进EPCs形成更多的集落，刺激人类EPCs分化成内皮细胞，并显着增强EPCs迁移。通过流式细胞术分析显示，NGF处理增加了C57BL / 6小鼠外周循环中EPCs的数量。此外，用NGF处理人EPC注射到小鼠中后促进了内皮细胞向损伤的颈动脉区域归巢。用双功能偶联剂N-琥珀酰基-3-（2-吡啶基二硫代）丙酸酯（SPDP）将去细胞化的大鼠血管基质与EDC交联胶原温育并结合NGF蛋白。将结合NGF的组织工程血管植入大鼠颈动脉1周和1个月。与对照相比，NGF结合的血管具有显着更高水平的内皮化和通畅性。这些结果表明，NGF可显着增加EPCs动员和归巢到血管移植物。神经营养因子如NGF具有体内构建组织工程血管的治疗潜力。

使用试剂原文信息：The concentrations of stromal cell-derived factor 1 a (SDF-1 a ) and VEGF in the serum of injured C57BL/6 mice were determined using an SDF-1 a ELISA Kit (Uscn life science & technology company, USA) and a VEGF ELISA Kit (Jingmei Biotech).